Pronzato, P., Mustacchi, G., Riccardi, F., Turletti, A., Michelotti, A., Natoli, C., et al. (2017). Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study. Intervento presentato a: 19th National Congress of Medical Oncology, Rome, Italy [10.1093/annonc/mdx424.024].
Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
Cazzaniga M.
2017
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
